Macitentan

Category: pharmacological

Aliases: Opsumit

Pharmacological Mechanism

Dual endothelin receptor antagonist — successor to bosentan with sustained tissue binding and once-daily dosing. PAH; hepatotoxicity is less than bosentan. Anemia + nasopharyngitis are the more common adverse effects.

Half-Life (t½)

PO: 16h

Dosing Guidelines

• PO: Typical 10mg (Range: 10 - 10 mg)

Target Organ Systems

• cardiovascular
• digestive
• immune-hematologic